OBIOOrchestra BioMed Holdings, Inc.
$5.73+110% 1Y
$5.73
$2.8752 weeks$6.36
The financials
Orchestra BioMed Holdings, Inc. by the numbers
Orchestra BioMed Holdings, Inc. (OBIO) reported revenue of $88K in Q2 2026 (quarter ended Jun 30, 2026), down 89% from the same quarter a year earlier. That came with a gross margin of 72% and net loss of $24M. For the full year FY2025, revenue was $33M (+1169% year on year) and net income −$53M.
| Income statement | Q2 2026 | Q2 2025 | Change |
|---|---|---|---|
| Revenue | $88K | $836K | −89% |
| Gross profit | $63K | $790K | −92% |
| Operating income | −$22M | −$19M | n/a |
| Net income | −$24M | −$19M | n/a |
| Diluted EPS | −$0.38 | −$0.50 | n/a |